To the full analysis
RemeGen stock: growth
688331.SSRemeGen reported $487.32M in revenue for fiscal 2025, up 89.3% on the prior year.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
124.5%
per year from 2018 to 2025
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | no data | 124.5% |
| Revenue per share | no data | no data |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $1.7M | −$40.48M | −$31.75M |
| 2019 | $0 | −$64.53M | −$52.18M |
| 2020 | $0 | −$104.65M | −$171.1M |
| 2021 | $213.53M | $41.43M | −$53.04M |
| 2022 | $115.79M | −$149.79M | −$303.11M |
| 2023 | $162.4M | −$226.63M | −$353.1M |
| 2024 | $257.47M | −$220.2M | −$216.23M |
| 2025 | $487.32M | $106.42M | −$21.57M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.